|Report ID : RNR-78409||Category : Biotechnology||Published Date : Jan-2016|
|Publisher : S&P Consulting||Pages : 140||Format : PDF|
Clustered regularly-interspaced short palindromic repeats also known as CRISPR is a gene editing tool. CRIPSR commercialization began in 2012 with emergence of number of startups and venture capitalists and showing their interest in infusing money into this technology. Academic and research firms are the main consumers of CRISPR gene editing tool followed by biotechnology companies. The number of patents for CRISPR is outclassing the patents of other gene editing tools such as ZFN and TALEN. The CRISPR market is driven by high demand for plasmids, synthetic genes and high quality gene slicing techniques. Growing drug discovery, biotechnology and proteomics markets are also driving the market growth. Considering the global CRISPR market growth, many new pharmaceutical and biotechnology companies are making strategic moves to enter this market. A significant increase in the R&D expenditure and growth of biotechnology and pharma industries are some of the key growth drivers and CRISPR is expected to be a beneficial tool for the entire genome editing market. There are lot of segments in which genome editing market is segmented. The out all the segments, CRISPR segment is expected to be the fastest growing segment of all. There are other segments also which are on the upfront for a solid growth. Besides CRISPR, cell line engineering is expected to contribute meaningfully to the global CRISPR market growth. This is a good sign as this expected growth will encourage leading pharma and biotechnology companies to expand their operations in other parts of the globe after America. In line with this fact, Asian market appears in the upfront for welcoming this growth. Considering the bright opportunities in these regions, many leading companies are strategically moving to these destinations. Moving on, there is a considerable increase in the healthcare spending in the recent times. The leading companies have increased their budget for R&D which is a good sign and will be a key growth driver for the global CRISPR market. Scientists are looking forward for CRISPR due to its special features. CRISPR has a unique feature of detecting specific sequence of letters in the genetics. The DNA can be cut at this point then. This is very important feature about CRISPR as with this, scientists can make alterations in the genetic code and make desired DNA. This will find great use in the development of GMO crops. In addition, CRISPR can also be used to detect the alterations in the human genome causing behavioral changes. This is a great achievement in the genome editing segment and it will contribute well to the field of genetics and medicine in the coming days. Companies profiled include: 1. Thermo Fisher Scientific 2. Editas Medicine 3. Caribou Biosciences 4. CRISPR therapeutics 5. Intellia 6. Cellectis 7. Horizon discovery PLC 8. Sigma Aldrich 9. Precision biosciences 10. GenScript 11. Sangamo Biosciences Inc. 12. Lonza group limited 13. Integrated DNA technologies 14. New England Biolabs 15. Oregene Technologies 16. Transposgen Biopharmaceuticals This Research report covers: 1. Historical data 2. Revenue forecasts, growth rates and CAGR up to 2021 3. Industry Analysis 4. Competitive Analysis 5. Key geographic growth data Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.
Table of Contents: 1. Executive Summary 1.1. Estimation Methodology 2. Market Overview 2.1. CRISPR- Introduction 2.2. Value chain analysis 2.3. Key buying criteria 2.4. Research and development 2.4.1. Patent analysis 2.5. CRISPR vs. Conventional gene editing tools 2.5.1. TALEN 2.5.2. ZFN 2.6. CRISPR: Novel initiatives 2.6.1. CRISPR/Cas9 technology 2.6.2. CRISPR as a gene editing tool to treat genetic disorders. 2.6.3. CRISP as a gene editing tool in drug development. 2.7. Strategic Recommendation and conclusion 3. Sector Analysis 3.1. Gene Editing Market 4. Market Determinants 4.1. Drivers 4.1.1. Rise in drug discovery market 4.1.2. Demand for synthetic genes 4.1.3. High prevalence of genetic birth disorders 4.1.4. Age related genetic disorders 4.1.5. Rise in the healthcare research and development budgets 4.1.6. Venture capital 4.2. Restraints 4.2.1. Ethical issues related to misuse of CRISPR gene editing tool 4.2.2 Limited awareness 4.2.3. Limited presence in Emerging markets 4.3. Opportunities 4.3.1 CRISPR gene editing can open the market for gene surgery. 4.3.2. Emerging contract research market in Asia 4.4. Challenges 4.4.1. Patent infringement 4.4.2. Presence of alternative gene editing tools 5. Market Segmentation 5.1. By Application 5.1.1. Genome Editing 5.1.2. Genetic engineering 5.1.3. gRNA Database/Gene Library 5.1.4. CRISPR Plasmid 5.1.5. Human Stem Cells 5.1.6. Genetically modified organisms/crops 5.1.7. Cell line engineering 5.2. By End user 5.2.1. Biotechnology companies 5.2.2. Pharmaceutical companies 5.2.3. Academic Institutes 5.2.4. Research and development institutes 5.3. Competitive Intelligence 5.3.1. Merger and Acquisitions 5.3.2. Innovation 5.3.3. Venture capital funding 6. Geographical Analysis 6.1. North America 6.1.1. United States 6.1.2. Canada 6.2. Europe 6.2.1. United Kingdom 6.2.2. France 6.2.3. Germany 6.2.4. Spain 6.2.5. Italy 6.3. Asia Pacific 6.3.1. China 6.3.2. Japan 6.3.3. India 6.4. Rest of the world 7. Company Profiling 1. Thermo Fisher Scientific 2. Editas Medicine 3. Caribou Biosciences 4. CRISPR therapeutics 5. Intellia 6. Cellectis 7. Horizon discovery PLC 8. Sigma Aldrich 9. Precision biosciences 10. GenScript 11. Sangamo Biosciences Inc. 12. Lonza group limited 13. Integrated DNA technologies 14. New England Biolabs 15. Oregene Technologies 16. Transposgen Biopharmaceuticals